CHARLES F. NAEGELE, M.D.
This content is PDF only. Please click on the PDF icon to access.
The precise place of streptomycin in the treatment of bacterial endocarditis has yet to be definitely established. It has been proposed1 as the drug of choice in cases caused by gram-negative bacilli susceptible, at least in vitro, to streptomycin. It must also be considered, however, in the small fraction of cases due to nonhemolytic streptococci in which the organism is initially resistant to penicillin, as well as the still smaller fraction, where penicillin resistance develops during therapy.
Relatively few reports1, 2, 3, 4 have appeared concerning the use of streptomycin in bacterial endocarditis, and the percentage of these cases due
NAEGELE CF. STREPTOMYCIN TREATMENT OF BACTERIAL ENDOCARDITIS DUE TO STREPTOCOCCUS VIRIDANS; REPORT OF TWO CASES1. Ann Intern Med. 1949;30:1049–1053. doi: 10.7326/0003-4819-30-5-1049
Download citation file:
Published: Ann Intern Med. 1949;30(5):1049-1053.
Cardiology, Endocarditis, Infectious Disease, Streptococcal Infections.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use